Видео с ютуба Elacestrant

Elacestrant: A New Weapon Against Advanced Estrogen Receptor-Positive Breast Cancer

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts

ERADICATE: elacestrant plus trastuzumab deruxtecan in HR+/HER2-low mBC

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

EMERALD: elacestrant vs physicians choice in ER+/HER2- breast cancer

ELCIN: elacestrant in CDK4/6 inhibitor-naïve ER+/HER2- metastatic breast cancer

ELECTRA: elacestrant and abemaciclib in patients with ER+, HER2- breast cancer

Breast Cancer Breakthroughs: Dr. Donald McDonnell explains how elacestrant was discovered in his lab

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer

ER+ metastatic breast cancer: Elacestrant and beyond

Elacestrant in ER+/HER2- mBC with ESR1-mut tumors: Overview of the EMERALD subgroup analyses

Dr Lloyd on the Effects of ESR1 Mutations on Elacestrant Outcomes in HR+ Advanced Breast Cancer

Можно ли принимать таблетки вместо инъекций при раке груди?

Oral SERDs Explained: A New Option for Breast Cancer Patients

EMERALD lead to the Elacestrant FDA Approval - OncBrothers in discussion w/ Dr. Virginia Kaklamani

Elacestrant in ER+/HER2- mBC: Overview of the EMERALD subgroup analysis

Elacestrant shows improved PFS in patients with ER-positive/HER2-negative metastatic breast cancer

: "Efficace in tumore al seno inibendo recettore estrogenico”

Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

Elacestrant